Download: Optimising Clinical Development & Speeding Patient Access to Orphan Drugs

In preparation for the 2014 World Orphan Drug Congress in Geneva, we have collated a number of interviews from some of the leading orphan drug developers. The industry-at-large are investing more and more resources into rare disease research, and numerous companies are now deploying the scientific, regulatory and strategic expertise to progressed an orphan drug to market. With over 7000 …

Download presentation- Evolving the Orphan Innovation Model: Partnership at the Heart of Sustainable Orphan Development

In November 2012 over 250 delegates participated in the 3rd Annual World Orphan Drug Congress Europe. This event covers strategies and opportunities from Clinical Development and R&D, Market Access, Pricing & Reimbursement , Corporate Development and Drug Repositioning & Indication Expansion. Attendees at this highly successful event were fortunate enough to hear this exciting presentation delivered by Geoffrey McDonough, President …

2013 Rare & Orphan Advocacy and Research (ROAR) Awards – VOTING NOW OPEN

Voting is now open for the 2013 ROAR Awards, the Rare and Orphan Drug Industries' Awards ceremony recognising and celebrating achievements across the commercial, patient and alliance organisations in the last 12 months. With 10 hotly contested awards open for nomination, make your votes count for individuals and organisations that have shown best in class in 2012/2013. Make your nominations …

Day 1 Review of the World Orphan Drug Congress – Geneva

Day 1 The World Orphan Drug Congress – Geneva Posted on November 30, 2012 by admin Written by Karl Simpson Well, the pharma industry's rare disease pioneers gather again this week for the World Orphan Drug Congress in Geneva. It is a two day seminar that focuses on three separate tracks, Clinical Development, Market Access/Pricing and Reimbursement as well as …